This suggests that ALDOB deficiency can inhibit the growth characteristics of colon cancer cells by inhibiting epithelial-mesenchymal transformation, and ALDOB can be used as a new therapeutic target, which is of great significance for the treatment and prognosis of colon cancer (71). Here, ALDOB is linked to malignant colon neoplasm.